VLS Stock Overview
A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Vita Life Sciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.80 |
| 52 Week High | AU$2.50 |
| 52 Week Low | AU$1.73 |
| Beta | 0.49 |
| 1 Month Change | -13.88% |
| 3 Month Change | -23.08% |
| 1 Year Change | 1.12% |
| 3 Year Change | -6.74% |
| 5 Year Change | 176.92% |
| Change since IPO | 958.82% |
Recent News & Updates
Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 23
Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035
Aug 28Recent updates
Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 23Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035
Aug 28Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market
Mar 22Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06
Mar 14Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 28A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)
Dec 20Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?
Aug 24If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late
May 14Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?
Mar 18Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?
Feb 17Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?
Jan 20Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching
Dec 22Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Nov 19
Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares
Jul 14Shareholder Returns
| VLS | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -2.2% | -1.1% | -2.0% |
| 1Y | 1.1% | -0.8% | 7.8% |
Return vs Industry: VLS exceeded the Australian Pharmaceuticals industry which returned -0.8% over the past year.
Return vs Market: VLS underperformed the Australian Market which returned 7.8% over the past year.
Price Volatility
| VLS volatility | |
|---|---|
| VLS Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: VLS has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: VLS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | n/a | Andrew O'Keefe | vitalifesciences.com |
Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. The company also offers various minerals, herbs, and superfoods. In addition, it provides products for therapeutic areas, such as nervous system; nutritionals; urinary health; weight management; immunity; skin, hair, and nails; liver and digestion; fertility, pregnancy, and postpartum; blood sugar management; cardiovascular health; pain and inflammation; men, women, and children’s health; antioxidants; bones, joints, and muscles; and eye health.
Vita Life Sciences Limited Fundamentals Summary
| VLS fundamental statistics | |
|---|---|
| Market cap | AU$99.85m |
| Earnings (TTM) | AU$9.39m |
| Revenue (TTM) | AU$79.17m |
10.7x
P/E Ratio1.3x
P/S RatioIs VLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VLS income statement (TTM) | |
|---|---|
| Revenue | AU$79.17m |
| Cost of Revenue | AU$32.77m |
| Gross Profit | AU$46.41m |
| Other Expenses | AU$37.01m |
| Earnings | AU$9.39m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.17 |
| Gross Margin | 58.61% |
| Net Profit Margin | 11.86% |
| Debt/Equity Ratio | 0% |
How did VLS perform over the long term?
See historical performance and comparisonDividends
5.0%
Current Dividend Yield55%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 14:31 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vita Life Sciences Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aidan Brooksby | Select Equities Pty Ltd |
| Shane Storey | Wilsons Advisory and Stockbroking Ltd. |